Cancer vaccines based on mRNA technology are showing encouraging results against some of the world’s hardest-to-treat cancers, including melanoma, pancreatic cancer and glioblastoma. The same technology used to develop COVID-19 vaccines at record speed is now being tested to train the immune system to recognise and destroy cancer cells. In addition, researchers say the field has become one of the…
Tag: Immunotherapy
-
Lower-Dose Immunotherapy Trials Expand Treatment Options
Ground-breaking new research suggests that dramatically lower doses or shorter courses of revolutionary immunotherapy drugs could be highly effective. This finding may eventually pave the way for wider global access to life-saving cancer treatments. Lower-dose immunotherapy trials are showing promising potential. Drugs like Merck & Co’s Keytruda and Bristol Myers Squibb Co’s Opdivo have transformed oncology. They boost survival rates…
-
Nobel Prize Highlights Advances in Cancer Immunotherapy
American scientists Mary Brunkow and Fred Ramsdell, alongside their Japanese colleague Shimon Sakaguchi, have been awarded the 2025 Nobel Prize in Physiology or Medicine. The prestigious award recognises their pivotal discoveries concerning regulatory T cells. These discoveries have fundamentally changed our understanding of the immune system. Additionally, they have paved the way for novel treatments for cancer and autoimmune disorders.…
-
Immunotherapy for Cancer and Early-Stage Success
Ground-breaking advancements in immunotherapy are poised to transform cancer care. New data reveal the effectiveness of these immune-boosting drugs in treating a wider range of cancers at their earlier stages. Previously established as life-extending treatments for advanced diseases, drugs such as Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imfinzi, and Roche’s Tecentriq are now demonstrating significant promise. They are preventing recurrence and…